Multiple Myeloma Coverage from Every Angle

EHA2021: Targeting BCMA in Early-Phase Study in Resistant Myeloma

By: Lauren Harrison, MS
Posted: Thursday, June 24, 2021

Elranatamab, a monoclonal antibody targeting B-cell maturation antigen (BCMA), was reported to have an acceptable safety profile and a wide therapeutic index when treating patients with relapsed or refractory multiple myeloma. Caitlin Costello, MD, of the University of California San Diego, presented this phase I study results on behalf of her colleagues at the European Hematology Association Virtual Congress (EHA2021; Abstract S192).

“These results demonstrate the safety and efficacy of elranatamab in this relapsed/refractory population, confirm the feasibility and potential of BCMA-directed immunotherapy for malignant plasma cell disorders, and support ongoing development of elranatamab for patients with multiple myeloma,” concluded the authors.

A total of 30 patients with multiple myeloma who had relapsed or became refractory to prior treatment were included in the study. Patients received single-agent elranatamab subcutaneously at doses of 80 (n = 6), 130 (n = 4), 215 (n = 4), 360 (n = 4), 600 (n = 6), and 1,000 (n = 6) μg/kg every week.

The overall response rate for patients receiving doses higher than 215 μg/kg was 75% (n = 15/20), including 6 patients with a partial response, 3 with a very good partial response, 1 with a complete response, and 5 with a stringent complete response. It took a median of 22 days for patients to achieve a response. Of note, three of the four patients who had received previous BCMA-directed therapy achieved a response.

The most common treatment-emergent any-grade adverse events were lymphopenia (80%), cytokine-release syndrome (73%), anemia (57%), injection-site reaction (53%), thrombocytopenia (53%), and neutropenia (40%). Cytokine-release syndrome typically occurred with the first dose of elranatamab, and T-cell proliferation increased in the peripheral blood. No patients experienced dose-limiting toxicities, the investigators reported. The recommended phase II dose based on these findings is 1,000 μg/kg weekly.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.